naporafenib
naporafenib: sourced relationships with 1 company · 3 clinical trials tracked.
naporafenib evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could naporafenib → ERAS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Erasca, Inc. (ERAS) Advanced or Metastatic NRAS-mutant Melanoma; Advanced or Met… | Phase 3 |
Clinical Trial Registry Records (3)
A Randomized, Open-label Phase III Study in Patients With Previously Treated Unresectable or Metastatic NRAS Mutant Cutaneous Melanoma Comparing the Combination of Naporafenib + Trametinib to Physician's Choice of Therapy (Dacarbazine, Temozolomide or Trametinib Monotherapy) With a Dose Optimization lead-in [SEACRAFT-2]
Primary endpoint: Stage 1:To select the optimal dose of naporafenib + trametinib to be studied in Stage 2
An Open-label Study to Assess the Safety and Efficacy of Naporafenib (ERAS-254) Administered With Trametinib in Previously Treated Patients With Locally Advanced Unresectable or Metastatic Solid Tumor Malignancies With RAS Q61X Mutations
Primary endpoint: To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors
A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma
Primary endpoint: Overall Response Rate
Frequently asked questions
Which companies have sourced relationships with naporafenib?
naporafenib has dated SEC/FDA relationship records for Erasca, Inc..
How many clinical trials involve naporafenib?
BioSniper tracks 3 clinical trials involving naporafenib.